Evidence map›Paper›PMID 42582193›Full record

ArticleFrontiers in immunology2026

Efficacy and safety of telitacicept in systemic lupus erythematosus: a single-center, retrospective, real-world study.

Li Yang, Jiayu Liu, Jinmei Zou, Jing Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Li Yang *Department of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jiayu Liu *Department of Emergency Medicine, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jinmei ZouDepartment of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Jing YangDepartment of Rheumatology, Mian Yang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To explore the real-world efficacy and safety of telitacicept in patients with systemic lupus erythematosus (SLE). Methods: This retrospective study included SLE patients treated with telitacicept for at least 3 months at Mianyang Central Hospital between January 2022 and December 2025. Baseline characteristics and clinical outcomes at 12, 24, and 52 weeks were assessed. Results: A total of 139 patients were enrolled in this study. The SLE Disease Activity Index 2000 (SLEDAI-2K) score significantly decreased from a baseline of 11.42 ± 4.68 to 4.623 ± 3.65, 2.42 ± 2.98, and 1.48 ± 2.58 at 12, 24, and 52 weeks, respectively ( Conclusion: In this real-world study, telitacicept combined with conventional therapy was associated with improvements in disease activity and organ functions in SLE with favorable safety.

Indexed as

Lupus Erythematosus, SystemicAdultAntibodies, AntinuclearComplement C3Complement C4FemaleHumansLupus NephritisMaleMiddle AgedRecombinant Fusion ProteinsRetrospective StudiesTreatment OutcomeAntibodies, AntinuclearComplement C3Complement C4Recombinant Fusion Proteinstelitaciceptefficacyreal-worldsafetysystemic lupus erythematosustelitacicept

Identifiers

PMID42582193
PMCPMC13457300

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.